0800 Immune
0800466863

Antigen review

Antigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Human papillomavirus

Over 72 countries have human papillomavirus (HPV) vaccine on their National Immunisation Programme. This report summarises new research into HPV vaccines and vaccination published during the past two and half years, from January 2013 to June 2016.

Antigen literature review for the New Zealand National Immunisation Schedule, 2016: Pneumococcal disease – in high-risk groups

This literature review was undertaken across scientific articles and systematic reviews published between January 2013 and October 2016 to examine this rapidly expanding topic. The aim was to identify who is at highest risk from invasive pneumococcal disesae and to evaluate the role of pneumococcal vaccination of adults and children in these high-risk groups in reducing disease with currently available conjugate and polysaccharide vaccines.

Antigen literature review for the New Zealand National Immunisation Schedule, 2016: Pneumococcal disease: ten-valent pneumococcal conjugate vaccine

This review was conducted to consider the safety of the ten-valent pneumococcal conjugate vaccine (PCV-10; Synflorix®) and its effectiveness in preventing pneumococcal disease, in particular invasive pneumococcal disease (IPD), in target age groups and the wider community when included in the childhood national immunisation schedule. The impact on otitis media incidence and non-invasive pneumococcal infections is also considered. Literature published between January 2013 and November 2016 is evaluated.

Antigen literature review for the New Zealand National Immunisation Schedule, 2016: Herpes zoster

This review summarises selected literature published from January 2013 to November 2016 on the use of the live attenuated varicella-zoster virus vaccine for the prevention of herpes zoster in adults from 50 years of age.

The focus of this review will be on the currently licensed live attenuated zoster vaccine. However, clinical trial data for the adjuvanted subunit zoster vaccine will be reviewed briefly, since regulatory approval is being sought for this vaccine and it is expected to be licensed during 2017.